Registration Dossier

Diss Factsheets

Administrative data

Description of key information

The test substance was shown to act as an antagonist at the nicotinic acetylcholine receptors in in vitro studies or when administered parenterally. However, no adverse effects in terms of neurotoxicity could be observed when given orally in repeated dose toxicity studies, indicating a rather poor uptake and limited bioavailability and/or fast metabolic transformation in less active metabolites. In addition, in a recent OECD 443 study investigating developmental neurotoxicity no adverse findings were reported up to the highest dose level applied.

Key value for chemical safety assessment

Additional information

Justification for classification or non-classification